Gonadorelin (GnRH) vs LL-37
Updated July 27, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Gonadorelin (GnRH) and LL-37 (also searched as LL-37 vs Gonadorelin (GnRH)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Gonadorelin (GnRH) centers on healing, while LL-37 leans toward healing. On indexed research, Gonadorelin (GnRH) is ahead (Gonadorelin (GnRH): 18 studies, Human evidence; LL-37: 11, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Gonadorelin (GnRH) is strongest for healing; LL-37 for healing.
- •Evidence: Gonadorelin (GnRH) Human evidence (18 studies) vs LL-37 Human evidence (11).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Gonadotropin-Releasing Hormone | GnRH Agonist
Human Cathelicidin | Antimicrobial Peptide
Gonadorelin (GnRH) vs LL-37: side-by-side
| Metric | Gonadorelin (GnRH) | LL-37 |
|---|---|---|
| Class | Sexual Health | Immune |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 18 | 11 |
| Research level | Extensively Studied | Well Studied |
| Strongest effect | Healing & recovery | Healing & recovery |
| Healing & recovery | 2.0 | 4.0▲ |
| Muscle & body comp | 0.0 | 0.0 |
| Metabolic & appetite | 0.0 | 0.0 |
| Neuro & mood | 1.0▲ | 0.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 0.0 | 4.0▲ |
| Skin & aesthetics | 0.0 | 0.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Gonadorelin (GnRH) | LL-37 |
|---|---|---|
| Mechanism | GnRH receptor agonist | Disrupts microbial membranes; modulates immune responses |
| Route | Subcutaneous injection | — |
| Half-life | ~20 min | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Gonadorelin (GnRH)?
Gonadorelin is synthetic GnRH, a decapeptide that stimulates pituitary release of LH and FSH in pulsatile fashion — used diagnostically and to support the reproductive hormone axis.
Full Gonadorelin (GnRH) profile, mechanism & studies →What is LL-37?
### LL-37 Summary LL-37 is a human cathelicidin antimicrobial peptide that plays a crucial role in the innate immune response, exhibiting antimicrobial, immunomodulatory, and wound healing properties. Its diverse functions make it a subject of interest in various fields of biomedical research.
Full LL-37 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | LL-37 | 4.0/5 effect signal |
| Neuro | Gonadorelin (GnRH) | 1.0/5 effect signal |
| Inflammation | LL-37 | 4.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Gonadorelin (GnRH) and LL-37?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Gonadorelin (GnRH) vs LL-37: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Gonadorelin (GnRH) has 18 approved studies indexed (Human evidence), and LL-37 has 11 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Gonadorelin (GnRH) or LL-37 better?
It depends on your goal. Gonadorelin (GnRH) is strongest for healing; LL-37 for healing. Gonadorelin (GnRH) has more indexed studies (18). See the goal-by-goal breakdown above.
Which has more research, Gonadorelin (GnRH) or LL-37?
Gonadorelin (GnRH) has 18 approved studies indexed (Human evidence); LL-37 has 11 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack Gonadorelin (GnRH) and LL-37?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Gonadorelin (GnRH) vs LL-37?
Gonadorelin (GnRH): no community-reported effects logged yet. LL-37: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Gonadorelin (GnRH) or LL-37 FDA-approved?
Gonadorelin (GnRH) is a research-use compound and is not FDA-approved. LL-37 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is LL-37 better than Gonadorelin (GnRH)?
For healing, LL-37 has the edge; for healing, Gonadorelin (GnRH) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Gonadorelin (GnRH) and LL-37 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 27, 2026.